Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug tolerance08.06.01.003--Not Available
Cardiac flutter02.03.02.012--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Application site swelling12.07.01.027; 08.02.01.0270.000313%Not Available
Secretion discharge08.01.03.0190.000470%Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Evans syndrome10.04.01.003; 01.06.01.0020.000627%Not Available
Nodule08.03.05.002--Not Available
Haemorrhoidal haemorrhage07.15.03.002; 24.10.02.001--
Transaminases increased13.03.04.036--Not Available
Foetal death18.01.02.003; 08.04.01.0110.002350%
Haemorrhage24.07.01.002--Not Available
Varices oesophageal24.10.02.004; 09.01.06.009; 07.15.05.0010.001567%Not Available
Fluid intake reduced14.05.10.001--Not Available
Pulmonary mass22.02.07.0040.000470%Not Available
Pneumatosis intestinalis07.11.01.0430.000627%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.008--Not Available
Testis cancer21.13.02.001; 16.25.03.0010.000470%Not Available
Metabolic disorder14.11.01.0010.003509%Not Available
Neutrophilic dermatosis23.03.03.059; 01.02.01.0130.000627%Not Available
Dysplasia08.03.04.0070.000470%Not Available
Dermatitis psoriasiform23.03.14.0040.000627%Not Available
Intestinal mass07.11.01.0100.000783%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000470%Not Available
Intestinal haemorrhage24.07.02.031; 07.12.03.0050.000313%Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Adhesion08.01.03.048--Not Available
Drug resistance08.06.01.0050.000940%Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene